Information Provided By: 
Fly News Breaks for March 20, 2017
NKTR
Mar 20, 2017 | 12:43 EDT
Roth Capital analyst Michael Higgins called Nektar's Phase 3 results for NKTR-181 "impressive" and said he expect management will now enter into negotiations to out-license the drug while meeting with the FDA. Higgins, who believes the drug is worth $2B by "conservatively" estimating its value at 3-4X peak sales, raised his price target on Nektar shares to $31 from $23 and reiterates a Buy rating on the stock.
News For NKTR From the Last 2 Days
There are no results for your query NKTR
